Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$155.29 USD
+0.46 (0.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $155.34 +0.05 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$155.29 USD
+0.46 (0.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $155.34 +0.05 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum D VGM
Zacks News
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics (DGX) Rides on Test Sales, Base Volume Gain
by Zacks Equity Research
Quest Diagnostics (DGX) continues to benefit from rapidly increasing molecular diagnostic testing volumes, driven by the massive spread of the new COVID-19 variant.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics and Quidel Corp.
by Zacks Equity Research
Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics,and Quidel Corp. are highlighted in this analyst blog.
3 Diagnostics Stocks in Focus Amid the Omicron Outbreak
by Riya Anand
Stocks like Thermo Fisher (TMO), QIAGEN (QGEN) and Quidel (QDEL) are expected to gain from increasing testing demand.
Forget DaVita (DVA), Buy These 3 Lucrative Medical Care Stocks
by Trina Mukherjee
With stocks offering dialysis services, including DaVita (DVA), facing several issues, it would be prudent to invest in medical care and services stocks like DGX, AMN and CODX instead for 2022.
Quest Diagnostics (DGX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Quest Diagnostics (DGX) could produce exceptional returns because of its solid growth attributes.
Has Quest Diagnostics (DGX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Quest Diagnostics (DGX) and LabCorp (LH) have performed compared to their sector so far this year.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Robust performance of the base business and COVID-19 testing volume gains are driving the top line for Quest Diagnostics (DGX).
Quest Diagnostics (DGX) Expands Testing Suite With NGS Test
by Zacks Equity Research
Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.
Quest Diagnostics' (DGX) COVID-19 Testing Demand Up in 3 Weeks
by Urmimala Biswas
According to Quest Diagnostics (DGX), as the nation is entering the holiday season, the importance of testing service is gaining more importance with regard to minimizing the risk of community exposure of COVID-19.
LabCorp (LH) Q3 Earnings Surpass Estimates, 2021 View Up
by Zacks Equity Research
LabCorp's (LH) Q3 Diagnostics revenues get significantly impacted by drop in sales for COVID-19 testing.
4 Medical Products Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
CONMED's (CNMD) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
CONMED's (CNMD) third-quarter earnings reflect strong segmental performance.
West Pharmaceutical (WST) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter earnings reflect segmental strong performance.
Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect robust performance across all its business units.
Align Technology (ALGN) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Continued momentum in Invisalign Clear Aligners and iTero scanners sales volumes drove Align Technology's (ALGN) revenues during the third quarter.
Edwards Lifesciences (EW) Beats on Q3 Earnings, Gross Margin Up
by Zacks Equity Research
Strong sales growth across all four products group along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) third-quarter revenues.
Abiomed (ABMD) Beats on Q2 Earnings, Lowers FY22 Guidance
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.
Thermo Fisher (TMO) Beats on Q3 Earnings, Raises 2021 View
by Zacks Equity Research
Thermo Fisher (TMO) delivers a strong quarterly performance, leveraging on a significant rebound in its base business.
Boston Scientific (BSX) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.
Masimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q3 sales.
Zacks.com featured highlights include: Olin, Quest Diagnostics, Equinor ASA, Teck Resources and Goldman Sachs
by Zacks Equity Research
Zacks.com featured highlights include: Olin, Quest Diagnostics, Equinor ASA, Teck Resources and Goldman Sachs
Ecolab (ECL) Q3 Earnings & Revenues Beat Mark, Margins Down
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its Q3 sales despite pandemic-led business challenges.
Is Quest Diagnostics (DGX) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.